ascendis pharma glp-1 receptor agonists weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Schematic illustration of monoagonists, dual

Archived from the original on 27 June 2022

It is essential to verify the patients understanding of the prescribed therapeutic regimen, clarify the benefits that can result from the therapy, discuss possible adverse events, and provide useful advice to minimize them, as well as simplify the therapeutic regimen when appropriate [73]

Mislabeled vials are a common source of dosing errors

GLP-1 RA-based treatments comply with these characteristics

However, unlike the relatively predictable conversion from MCI to AD, the progression from hyposmia or rapid eye movement sleep behavior disorder to PD is variable [107], complicating the assessment of GLP-1RAs efficacy in preventing phenotype conversion

Its main actions include: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppressing glucagon release, which reduces hepatic glucose production Slowing gastric emptying, which moderates post-meal glucose spikes Promoting satiety through central nervous system pathways, thereby reducing appetite GIP is released by K-cells in the proximal small intestine and shares some functions with GLP-1, particularly in enhancing insulin secretion after meals